Astellas to sale off the Oncology line by 2015

Quote
Japan Economy is so bad and affects their private sector such as Astellas. Makes sense for Astellas to sell the Oncology franchise to save something more important in Japan, JOBS!
 












It does not matter when Enzalutamide patent expires, what is deteramental is patent expiration of Aburaterone Acetate (Zytiga), 2016, which is the biggest and leading comparator. Once Zytiga goes generic, Enzalutamide (Xtandi) will have to compete with a cheaper drug. This already has had huge impact on duration of use of Xtandi in post Zytiga as well mandate by most insurance companies in USA for Physicians to write Zytiga first as even now they are cheaper than Xtandi BUT equation will totally change in 2016 as Physicians will use a generic cheaper and effective drug, Zytiga, off label in more earlier in disease and mandate for all USA and EX USA payers to use Zytiga, generic drug, first. This means not much predicted income from Xtandi. Tarceva also goes off patent by late 2017 and similar destiny awaits them. Astellas has no other drug in pipeline. That is why they have been talking to few companies trying to generate more money now by dumping Oncology in order to raise money and concentrate in other areas, Pain, rare disease etc.
 












Method of use patent for Abiraterone Acetate plus prednisone is something new, Patent 8822438 Expires on: August 24, 2027 But most likely will be challenged in courts by generic makers of Abiraterone when Abiraterone acetate goes generic. Patent Expirey for Abiraterone Actate is stated in FDA filing, FDA Orange Book, as well with US Patent Office. Patent 5604213 Expires on: Dec 13, 2016. Loss of Exclusivity for Abiraterone Acetate: NCE April 28, 2016 and I-663 Dec 10, 2015. That means less than a year from now, Generic drug makers are able to develop Abiraterone Acetate and Challenge the Method of use patent in court.

This has happened before and most if not all the time, courts have sided with Generic drug makers.

Impact of generic Abi on 2016 in USA will be huge in other products such as Xtandi and in EU, loss of Exclusivity of 2020 will finish the Abi competitors.

Good for patients that will be able to receive these drugs in a cheaper way.
 






Anonymous said:
They should sell the Oncology division. Over heard this older lady who claimed to be a head of development bragging about how much money she is making and how little work she has been doing. She was claiming, she was retiring from her last job but they brought her here and are giving her boat load of money to do nothing.

Did some research and yes, she is a Pharm.D., used to be a project director at Millenium BUT now is a SVP of Oncology development here. You figure it out. This shows we are not serious about Oncology. What a bunch of losers.
Click to expand...

Was this lady by any chance African American?
 












As one of the authors has mentioned above, method of use patent is NOT enforceable, this is 2027 for Abiraterone Acetate, but have always been challenged by courts in favor of generic companies.
Abiraterone true patents expires by end of this year and generic Abiraterone would be available by end of 2016.
 






Anonymous said:
As one of the authors has mentioned above, method of use patent is NOT enforceable, this is 2027 for Abiraterone Acetate, but have always been challenged by courts in favor of generic companies.
Abiraterone true patents expires by end of this year and generic Abiraterone would be available by end of 2016.
Click to expand...

Need to jump ship soon. Just lost a big player in Stephanie from Iowa. Not good.
 












Anonymous said:
Whats a BIG player mean??? And just one rep leaving doesnt shake up oncology that much? It's another person selling for Genentech. Like they need ONE more person to sell in closed access offices?
Click to expand...
Closed access might apply to Astellas. Genentech has carte Blanche in many offices., you lose a big player that could show 95 percent of your reps how it is done. Why stay at Astellas for 95k a year when you can go to Genentech and start at 150k. She was able to break the bank.
 






Anonymous said:
Closed access might apply to Astellas. Genentech has carte Blanche in many offices., you lose a big player that could show 95 percent of your reps how it is done. Why stay at Astellas for 95k a year when you can go to Genentech and start at 150k. She was able to break the bank.
Click to expand...

Genentech is doing awful things in their system with fake calls and manipulation. The management team is horrible. NO ONE is a big player anymore. Astellas is a joke...always has been but Genentech...their time is coming...too many people tired of them and avastin a serious issue to sell with speciality pharmacy issues...Genentech reps dont work at all..so i guess she can get 150K to work for a jerk manager and lie about calls..go to their board and read what's going on in that company.
 






Anonymous said:
Genentech is doing awful things in their system with fake calls and manipulation. The management team is horrible. NO ONE is a big player anymore. Astellas is a joke...always has been but Genentech...their time is coming...too many people tired of them and avastin a serious issue to sell with speciality pharmacy issues...Genentech reps dont work at all..so i guess she can get 150K to work for a jerk manager and lie about calls..go to their board and read what's going on in that company.
Click to expand...

Someone has an anger management issue with Genentech? You do not like our fleet of company provided Mercedes, Jags, Porsche, BMW and Lexus? You do not like our 5 day work months? Bonus over 80k last year, corporate bonus over 15k and base plus bonus over 225k. Went to Cabo already this year, Europe later in the year and new Mercedes on Monday, how cool is that? Figuring in meetings, left the house just over 500 hours last year, or about 5 days a month. Heck, I knew a manager that worked with one of his reps 3 hours in 11 months. He gets over 300k, major scratch for doing that. Screw specialty pharmacy, we picked up 200-300 million by the move. We own Oncology if you have not noticed. Fake calls are the norm and figured in with ZS. The majority of reps have over a 50 percent fake call rate, get over it. I love calls on dead docs, you don't get feedback ,but you don't get push back either.

If you get to the big leagues with Genentech, let us know. Single A at Astellas sucks for sure . Now excuse me, planning the European vacation.
 






Anonymous said:
Someone has an anger management issue with Genentech? You do not like our fleet of company provided Mercedes, Jags, Porsche, BMW and Lexus? You do not like our 5 day work months? Bonus over 80k last year, corporate bonus over 15k and base plus bonus over 225k. Went to Cabo already this year, Europe later in the year and new Mercedes on Monday, how cool is that? Figuring in meetings, left the house just over 500 hours last year, or about 5 days a month. Heck, I knew a manager that worked with one of his reps 3 hours in 11 months. He gets over 300k, major scratch for doing that. Screw specialty pharmacy, we picked up 200-300 million by the move. We own Oncology if you have not noticed. Fake calls are the norm and figured in with ZS. The majority of reps have over a 50 percent fake call rate, get over it. I love calls on dead docs, you don't get feedback ,but you don't get push back either.

If you get to the big leagues with Genentech, let us know. Single A at Astellas sucks for sure . Now excuse me, planning the European vacation.
Click to expand...

WHoever wrote this from whatever company needs to be fired and turned in to the OIG. Totally sick and horrible representation of any company.
 












Anonymous said:
WHoever wrote this from whatever company needs to be fired and turned in to the OIG. Totally sick and horrible representation of any company.
Click to expand...

Living under a rock? Have you seen the fleet of vehicles that Genentech reps drive? I pulled up at a clinic, one in a jag and one in a Mercedes. European vacations are the norm. Talk to a pharmacy director, the Cancer centers easily forked over 200-300 mil more for Avastin, Rituxan and Herceptin in the US due to the distribution model.

Reality sucks.
 






Anonymous said:
Living under a rock? Have you seen the fleet of vehicles that Genentech reps drive? I pulled up at a clinic, one in a jag and one in a Mercedes. European vacations are the norm. Talk to a pharmacy director, the Cancer centers easily forked over 200-300 mil more for Avastin, Rituxan and Herceptin in the US due to the distribution model.

Reality sucks.
Click to expand...

Reality says this entire strand needs to be printed and sent in. It's not right and reps who continue being arrogant on all this need to get what they truly deserve. This isnt right for patients and people who are suffering. It has nothing to do with living under a rock..its plain wrong..
 






Anonymous said:
Reality says this entire strand needs to be printed and sent in. It's not right and reps who continue being arrogant on all this need to get what they truly deserve. This isnt right for patients and people who are suffering. It has nothing to do with living under a rock..its plain wrong..
Click to expand...

Hate to break the news to you. Genentech helped underwrite the 2012 inauguration. Do you really think the government cares? Be real.
 






Anonymous said:
Genentech is doing awful things in their system with fake calls and manipulation. The management team is horrible. NO ONE is a big player anymore. Astellas is a joke...always has been but Genentech...their time is coming...too many people tired of them and avastin a serious issue to sell with speciality pharmacy issues...Genentech reps dont work at all..so i guess she can get 150K to work for a jerk manager and lie about calls..go to their board and read what's going on in that company.
Click to expand...

Dude, we're hiring!! 200k a year to do nothing. OK, a few fake calls per week, but you can go out and buy a nice sports car as your company car, plenty of vacation and relaxation.

Work is optional. Great gig.
 






Just came back from vacation and I saw Josh S is gone. What does that mean for Oncology? Not that he did much but maybe a signal that things are not improving. We need more Onc drugs. What is after Xtandi?
 






Top Bottom
Back
Quote